Aegon (AGN) investor relations material

Executive summary

• Achieved robust commercial and financial results in H1 2026, with operating result up 9% to EUR 804 million and net result stable at EUR 608 million, driven by strong business growth and favorable markets.

• Operating capital generation rose 27% to EUR 416 million, reflecting improved claims experience and business momentum.

• Announced sale of Aegon UK to Standard Life for GBP 2.0 billion, with strategic focus on US market and relocation of headquarters to New York City.

• Interim dividend increased by 11% to EUR 0.21 per share; share buyback program for 2H 2026 raised by EUR 150 million to EUR 350 million.

• Extraordinary General Meeting set for October 8, 2026, to approve US redomiciliation; leadership changes include CEO term extension and new President/COO.

Financial highlights

• Operating result: EUR 804 million (+9% YoY); Net result: EUR 608 million (flat YoY); OCG: EUR 416 million (+27% YoY); Free cash flow: EUR 392 million.

• Group solvency ratio at 169% (down from 184% at year-end 2025), mainly due to capital distributions and market impacts.

• Cash capital at holding reached EUR 1.7 billion; valuation equity per share increased by 4% to EUR 9.42.

• Gross financial leverage rose to EUR 5.0 billion (26.0% ratio) due to new bond issuance.

• Return on equity: 16.7% (up from 15.4% YoY); CSM after tax: EUR 5.45 billion.

Outlook and guidance

• Targeting ~5% annual growth in operating result and free cash flow, and >5% annual dividend per share growth through 2027.

• Updated ambitions reflect sale of Aegon UK and transfer of Transamerica Asset Management, with group operating result run-rate of EUR 1.3–1.5 billion and OCG run-rate of EUR 0.7–0.75 billion by 2027.

• Free cash flow run-rate expected to increase ~5% per annum, excluding Aegon UK remittances.

• Accelerated implementation of Bermuda solvency framework by 2026.

• Targeting around EUR 1 billion cash capital at holding by year-end 2026.